QUÉBEC CITY, Jan. 26, 2012
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that Jacek
Pinski, MD, PhD, Associate Professor of Medicine at the
Norris Comprehensive Cancer Center of the University of Southern California, will present
updated interim results from a Phase 1 clinical trial in prostate
cancer with AEZS-108 (zoptarelin doxorubicin), the Company's
targeted cytotoxic luteinizing hormone releasing hormone ("LHRH")
analog. The presentation will take place on Thursday, February 2, 2012, during the
American Society of Clinical Oncology Genitourinary
Cancers Symposium which will be held February 2-4, 2012 in San Francisco.
Poster D3: |
"A Phase 1 trial of AEZS-108 in castration - and
taxane-resistant prostate cancer ", S.V. Liu, A.V. Schally,
T.B. Dorff, D.D. Tsao-Wei, S.G. Groshen, S. Xiong, D. Hawes, D.I.
Quinn, Y.C. Tai, N.L. Block, J. Engel, J. K. Pinski |
Presenter: |
Jacek Pinski, MD, PhD |
Session: |
General Poster Session A: Prostate Cancer |
Date and
time: |
Thursday, February 2, 2012, 11:45 a.m. - 1:15 p.m.
(Pacific) |
Venue: |
Golden Gate Hall, San Francisco Marriot Marquis |
About AEZS-108
AEZS-108 (zoptarelin doxorubicin) represents a new targeting
concept in oncology using a hybrid molecule composed of a synthetic
peptide carrier and a well-known chemotherapy agent, doxorubicin.
AEZS-108 is the first intravenous drug in a clinical study that
directs the chemotherapy agent specifically to LHRH-receptor
expressing tumors, resulting in more targeted treatment with less
damage to healthy tissue. The product has successfully completed
Phase 2 studies for the treatment of endometrial and ovarian
cancer, and is also in Phase 1/2 trials in prostate and bladder
cancer. AEZS-108 has been granted orphan-drug designation by the
FDA and orphan medicinal product designation from the EMA for the
treatment of ovarian cancer. Aeterna Zentaris owns the worldwide
rights to AEZS-108.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer. The Company's innovative
approach of "personalized medicine" means tailoring treatments to a
patient's specific condition and to unmet medical needs. Aeterna
Zentaris' deep pipeline is drawn from its proprietary discovery
unit providing the Company with constant and long-term access to
state-of-the-art therapeutic options. For more information please
visit www.aezsinc.com
SOURCE AETERNA ZENTARIS INC.